Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Gowda

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Hastings Center Report|January 14, 2012
Case study. Confidentiality and its limits. CommentaryJohn D Lantos, Sonia Gowda
Therapeutic Advances in Hematology|August 6, 2016
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaMili Arora, Sonia Gowda, Joseph Tuscano
Journal of Gastrointestinal Oncology|May 17, 2024
Treatment of <i>BRAF</i> V600E mutant gastrointestinal stromal tumor with dabrafenib: a case reportSonia Gowda, Lyndsey Sandow, Michael C Heinrich
European Journal of Haematology|December 14, 2021
Assessing the risk of thromboembolism in cancer patients receiving immunotherapyAbhishek Goel, Arjun Khorana, Thomas Kartika, et al.
JCO Precision Oncology|April 28, 2025
Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch SyndromeSonia Gowda, Fei Song, Shannon Young, et al.
Plos One|January 6, 2018
A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activationGustavo A Barisone, Robert T O'Donnell, Yunpeng Ma, et al.
Thrombosis Research|June 6, 2022
Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosisHannah McMurry, Jean M G Sabile, Benjamin Elstrott, et al.
Thrombosis Research|July 11, 2022
Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignanciesRajat Thawani, Thomas Kartika, Benjamin Elstrott, et al.
Ejhaem|August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessationRebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Hastings Center Report|January 14, 2012
Case study. Confidentiality and its limits. CommentaryJohn D Lantos, Sonia Gowda
Therapeutic Advances in Hematology|August 6, 2016
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaMili Arora, Sonia Gowda, Joseph Tuscano
Journal of Gastrointestinal Oncology|May 17, 2024
Treatment of <i>BRAF</i> V600E mutant gastrointestinal stromal tumor with dabrafenib: a case reportSonia Gowda, Lyndsey Sandow, Michael C Heinrich
European Journal of Haematology|December 14, 2021
Assessing the risk of thromboembolism in cancer patients receiving immunotherapyAbhishek Goel, Arjun Khorana, Thomas Kartika, et al.
JCO Precision Oncology|April 28, 2025
Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch SyndromeSonia Gowda, Fei Song, Shannon Young, et al.
Plos One|January 6, 2018
A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activationGustavo A Barisone, Robert T O'Donnell, Yunpeng Ma, et al.
Thrombosis Research|June 6, 2022
Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosisHannah McMurry, Jean M G Sabile, Benjamin Elstrott, et al.
Thrombosis Research|July 11, 2022
Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignanciesRajat Thawani, Thomas Kartika, Benjamin Elstrott, et al.
Ejhaem|August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessationRebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
Pageof 1